213 related articles for article (PubMed ID: 19284319)
1. Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol.
Yang Y; Wu K; Yuan H; Yu M
J Ocul Pharmacol Ther; 2009 Apr; 25(2):163-71. PubMed ID: 19284319
[TBL] [Abstract][Full Text] [Related]
2. Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle Glaucoma--a pilot study.
Yuan H; Yu M; Yang Y; Wu K; Lin X; Li J
J Ocul Pharmacol Ther; 2010 Oct; 26(5):497-501. PubMed ID: 20925579
[TBL] [Abstract][Full Text] [Related]
3. Effect of
Moshetova LK; Soshina MM; Turkina KI; Grishina EA; Sozaeva ZA; Kachanova AA; Akmalova KA; Ivashchenko DV; Zastrozhin MS; Fisenko VP; Sychev DA
Drug Metab Pers Ther; 2023 Jun; 38(2):143-148. PubMed ID: 36001461
[TBL] [Abstract][Full Text] [Related]
4. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
Konstas AG; Maltezos A; Mantziris DA; Sine CS; Stewart WC
Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
[TBL] [Abstract][Full Text] [Related]
5. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
7. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma.
Feldman RM; Stewart RH; Stewart WC; Jia G; Smugar SS; Galet VA
Curr Med Res Opin; 2008 Aug; 24(8):2403-12. PubMed ID: 18627642
[TBL] [Abstract][Full Text] [Related]
8. [Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma].
Schmidt KG; von Rückmann A; Becker R; Pillunat LE
Klin Monbl Augenheilkd; 1999 Dec; 215(6):361-6. PubMed ID: 10637801
[TBL] [Abstract][Full Text] [Related]
9. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.
Schenker H; Maloney S; Liss C; Gormley G; Hartenbaum D
Clin Ther; 1999 Jan; 21(1):138-47. PubMed ID: 10090431
[TBL] [Abstract][Full Text] [Related]
10. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
[TBL] [Abstract][Full Text] [Related]
11. A short term study of the additive effect of timolol and brimonidine on intraocular pressure.
Arici MK; Sayici M; Toker M; Erdoğan H; Topalkara A
Eye (Lond); 2002 Jan; 16(1):39-43. PubMed ID: 11913886
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD and 0.5% levobunolol hydrochloride BID in patients with ocular hypertension or open-angle glaucoma.
Halper LK; Johnson-Pratt L; Dobbins T; Hartenbaum D
J Ocul Pharmacol Ther; 2002 Apr; 18(2):105-13. PubMed ID: 12002664
[TBL] [Abstract][Full Text] [Related]
13. Effect of changing from concomitant timolol pilocarpine to bimatoprost monotherapy on ocular blood flow and IOP in primary chronic angle closure glaucoma.
Agarwal HC; Gupta V; Sihota R
J Ocul Pharmacol Ther; 2003 Apr; 19(2):105-12. PubMed ID: 12804055
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects.
Fuchsjager-Mayrl G; Markovic O; Losert D; Lucas T; Wachek V; Muller M; Schmetterer L
Mol Vis; 2005 Sep; 11():811-5. PubMed ID: 16205624
[TBL] [Abstract][Full Text] [Related]
16. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
Bucci MG
J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure response to topical beta-blockers associated with an ADRB2 single-nucleotide polymorphism.
McCarty CA; Burmester JK; Mukesh BN; Patchett RB; Wilke RA
Arch Ophthalmol; 2008 Jul; 126(7):959-63. PubMed ID: 18625943
[TBL] [Abstract][Full Text] [Related]
18. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
[TBL] [Abstract][Full Text] [Related]
19. A comparative analysis of the effects of the fixed combination of timolol and dorzolamide versus latanoprost plus timolol on ocular hemodynamics and visual function in patients with primary open-angle glaucoma.
Siesky B; Harris A; Sines D; Rechtman E; Malinovsky VE; McCranor L; Yung CW; Zalish M
J Ocul Pharmacol Ther; 2006 Oct; 22(5):353-61. PubMed ID: 17076630
[TBL] [Abstract][Full Text] [Related]
20. Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma.
Ergin A; Ornek K; Güllü R; Bulcun E; Ekici M; Ekici A
J Ocul Pharmacol Ther; 2009 Oct; 25(5):463-6. PubMed ID: 19552600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
